SOURCE: XenaCare Holdings, Inc.

XenaCare Holdings, Inc.

April 16, 2010 08:27 ET

XenaCare Holdings Announces First Quarter Sales of $895,487 and Its First Quarterly Net Income of $109,485, Positioning the Company With a Positive Net Worth for the First Time; Additional Information About Company Financial Results for the First Quarter of 2010 Will Be Contained in the Quarterly Report on Form 10-Q to Be Filed With the SEC on or About April 20, 2010

XenaCare's President and CEO Frank Rizzo Explained, "The Results Are Due to a Close Professional Collaboration Between XenaCare's 205 Brokers, Nutra Pharma and Song Plus, Its New York Advertising Firm That Has Built Tremendous Momentum for Cobroxin That Is Being Accepted in All Forms of Distribution."

DELRAY BEACH, FL--(Marketwire - April 16, 2010) -  XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the branding, marketing and retail distribution started introducing Cobroxin on E commerce and 18,000,000 catalogues in the fourth Quarter of 2009. The penetration into Mass Food and Drugstore distribution is ahead of schedule and increasing every day.

"Sales of Cobroxin have already exceeded our projections for the beginning of this year," explained Frank Rizzo, President and CEO of XenaCare Holdings. We realized the success of Cobroxin when the www.Cobroxin.Com website sales covered our fixed overhead. "Reorder rates from our customers have been very strong at all levels of our distribution grid and have required us to reorder inventory five times from Nutra Pharma since placing our initial order for the product," he added.

To support sales of Cobroxin, XenaCare has committed to a $4 million print advertising campaign for the first 12 months. This campaign includes advertisements in Health, Prevention, Self, Soap Opera Digest, Working Mother, Woman's Day, Shape, Martha Stewart, Redbook, Ladies Home Journal, Allure, Wired, Web M.D. and Arthritis Today magazines.

In addition to its national print campaign, the Company has contracted with the Home Shopping Group to organize direct response television commercials that began airing in March 2010. Additionally, the Company has committed to a $3 million television broadcast campaign.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. The drug is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

  • All Natural

  • Non-Addictive

  • Non-Narcotic

  • Non-Opiate

  • Long Lasting

XenaCare Holdings was granted a license by Nutra Pharma Corporation to market and distribute Cobroxin within the United States.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.

Cautionary Note Concerning Forward-Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans for specific advertising and marketing campaigns supporting Cobroxin are forward looking statement and subject to change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company's current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at

Contact Information

  • Contact:
    XenaCare Holdings
    Frank Rizzo
    Email Contact